De novo ulcerative colitis after kidney transplantation treated with infliximab

• Published in: CEN case reports 2021-11, Vol.10 (4), p.500-505
• Main Authors: Oki, Rikako, Hidaka, Sumi, Sasaki, Akiko, Teshima, Shinichi, Mochida, Yasuhiro, Miyake, Katsunori, Ishioka, Kunihiro, Moriya, Hidekazu, Ohtake, Takayasu, Kobayashi, Shuzo
• Format: Article
• Language: English
• Subjects: Case Report; Colitis, Ulcerative - drug therapy; Gastrointestinal Agents - therapeutic use; Humans; Infliximab - therapeutic use; Kidney Transplantation; Male; Medicine; Medicine & Public Health; Middle Aged; Nephrology; Postoperative Complications - drug therapy; Urology
• ISSN: 2192-4449; 2192-4449
• DOI: 10.1007/s13730-021-00599-6

Diarrhea is a common complication in kidney transplant recipients. Common causes of diarrhea include infection, side effect from medication, rejection, and malignancy. A less common but important cause of diarrhea is de novo inflammatory bowel disease (IBD). This is unexpected, as these patients are already immunosuppressed. Herein, we present the case of a 45-year-old man with end-stage kidney disease because of focal segmental glomerulosclerosis who underwent preemptive kidney transplantation, with his mother as donor. His immunosuppressive regimen included methylprednisolone, mycophenolate mofetil, and tacrolimus. He had no episodes of graft dysfunction, rejection, or infectious events. Two and a half years post-transplantation, he developed bloody diarrhea. After excluding infections, colonoscopy was performed and revealed edematous mucosa and erythema with pigmentation, which are typical findings in ulcerative colitis. Despite therapy with 5-aminosalicylate and granulocyte monocyte apheresis, he presented with massive bloody diarrhea. We initiated infliximab, an anti-tumor necrosis factor-α (TNF-α) agent. He responded very well and achieved remission within 6 months after initiation of infliximab, while administration of the other immunosuppressants was maintained. His course was uneventful and no complications developed. Management of immunosuppressants for de novo IBD after organ transplantation is complicated, because treatment of IBD, graft function protection, and prevention of infection must be considered. Therefore, cooperation between transplantation physicians and gastroenterologists is essential during therapy.